Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology
-$0.72 today
- Market cap
- $1.35B
- Beta
- 0.75
- P/E (TTM)
- -13.4
- EPS (TTM)
- -$2.12
Volume 0.47M
Average 0.96M
TYRA Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Tyra Biosciences, Inc.NASDAQ: TYRA
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $138K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $138K.
Context
- Cost of revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $138K or moves back toward the trailing-twelve-month quarterly average of $34.5K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How TYRA compares with its peers on the latest reported figures
- TYRA's LTM Mar 2026 cost of revenue of $138K is the 8th highest of the 11 companies compared; the peer median is $5.94M.
- Its year-over-year change of +9.5% is the 2nd highest of 7, against a peer median of +0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.23M | -18.4% | +80.2% | 30.1% | |
| LTM Mar 2026 | $21.94M | — | — | 77.7% | |
| LTM Jun 2026 | $10.3M | -1.0% | — | 6.1% | |
| LTM Mar 2026 | $9.91M | -79.7% | +34.1% | 45.9% | |
| LTM Mar 2026 | $8.06M | — | — | 16.3% | |
| LTM Mar 2026 | $3.83M | +1795.5% | — | 5.3% | |
| LTM Mar 2026 | $320K | +5.3% | — | — | |
| LTM Mar 2026 | $138K | +9.5% | — | — | |
| LTM Mar 2026 | $79K | +2.6% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding TYRA) | $5.94M | +0.8% | +57.1% | 23.2% | |
Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 20.64M | 43.01M | 62.52M | 80.08M | 102.93M |
| Selling, General & Admin | 5.65M | 15.92M | 17.43M | 24.1M | 29.83M |
| Operating Expenses | 26.29M | 58.93M | 79.95M | 104.18M | 132.76M |
| Depreciation & Amortization | 140K | 296K | 357K | 519K | 546K |
| EBITDA | (26.15M) | (55.03M) | (68.78M) | (85.96M) | (119.4M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (26.29M) | (58.93M) | (79.95M) | (104.18M) | (132.76M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13K | 3.65M | 10.81M | 17.7M | 12.82M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (6K) | 3.6M | 10.81M | 17.7M | 12.82M |
| Income Before Tax | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.63) | (1.23) | (1.62) | (1.51) | (2.01) |
| EPS (Diluted) | (0.63) | (1.23) | (1.62) | (1.51) | (2.01) |
| Weighted Avg Shares | 41.44M | 41.88M | 42.7M | 57.22M | 59.6M |
| Weighted Avg Shares (Diluted) | 41.44M | 41.88M | 42.7M | 57.22M | 59.6M |
Tyra Biosciences, Inc.
NASDAQ:TYRA
Intrinsic Alpha fair value
Locked
Current Price
$19.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.